Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1981 Jul;43(3):459–465.

The effect of combined chemotherapy on suppressor T-cell activity in Mycobacterium simiae-infected mice.

S R Watson, L K Auclair, F M Collins
PMCID: PMC1555032  PMID: 6454654

Abstract

Specific pathogen-free B6D2 mice were infected with 10(6) or 10(8) viable Mycobacterium bovis (BCG Pasteur) or Mycobacterium simiae and the in vivo growth curves were correlated with the levels of delayed hypersensitivity developed against a cytoplasmic protein antigen (CPA) injected into a hind footpad at increasing time intervals after infection. Half of the heavily infected, anergic mice were placed on a regimen of 10 mg of rifampin, 5 mg of amikacin and 2 mg of clofazimine per 100 ml of drinking water 2 or 8 weeks into the infection. The number of viable mycobacteria recovered from the lungs and spleens of the treated mice (compared with the corresponding drug-free controls) were reduced by up to 10,000-fold over a 3-month treatment period. Spleen cells were harvested at increasing time intervals from the drug-treated and control mice and T-cell enriched suspensions were tested for blastogenic responsiveness to phytohaemagglutinin (PHA) and to the specific CPA mitogen. The early (day 14) peak in tritiated thymidine ([3H]-TdR) uptake was followed by a sharp drop to near background levels. Cell-mixing experiments demonstrated the presence of a suppressor T-cell population in the heavily infected spleens of the M. simiae-infected mice. The suppressor-cell effect was substantially reduced following combined drug therapy although the specific CPA-mediated response was less affected than the non-specific PHA-mediated response.

Full text

PDF
459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bullock W. E. Anergy and infection. Adv Intern Med. 1976;21:149–173. [PubMed] [Google Scholar]
  2. CORPE R. F. CLINICAL ASPECTS, MEDICAL AND SURGICAL, IN THE MANAGEMENT OF BATTEY-TYPE PULMONARY DISEASE. Dis Chest. 1964 Apr;45:380–382. doi: 10.1378/chest.45.4.380. [DOI] [PubMed] [Google Scholar]
  3. Collins F. M., Mackaness G. B. The relationship of delayed hypersensitivity to acquired antituberculous immunity. I. Tuberculin sensitivity and resistance to reinfection in BCG-vaccinated mice. Cell Immunol. 1970 Sep;1(3):253–265. doi: 10.1016/0008-8749(70)90047-x. [DOI] [PubMed] [Google Scholar]
  4. Collins F. M., Morrison N. E., Montalbine V. Immune response to persistent mycobacterial infection in mice. Infect Immun. 1978 May;20(2):430–438. doi: 10.1128/iai.20.2.430-438.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Collins F. M., Watson S. R. Effect of chemotherapy on suppressor T cells in BCG-infected mice. Immunology. 1980 Aug;40(4):529–537. [PMC free article] [PubMed] [Google Scholar]
  6. Collins F. M., Watson S. R. Suppressor T-cells in BCG-infected mice. Infect Immun. 1979 Aug;25(2):491–496. doi: 10.1128/iai.25.2.491-496.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Collins F. M., Wayne L. G., v Montalbine The effect of cultural conditions on the distribution of Mycobacterium tuberculosis in the spleens and lungs of specific pathogen-free mice. Am Rev Respir Dis. 1974 Aug;110(2):147–156. doi: 10.1164/arrd.1974.110.2.147. [DOI] [PubMed] [Google Scholar]
  8. Convit J., Ulrich M. Recent advances in the immunology of leprosy. Int J Dermatol. 1976 Apr;15(3):157–170. doi: 10.1111/j.1365-4362.1976.tb00679.x. [DOI] [PubMed] [Google Scholar]
  9. Gangadharam P. R., Candler E. R. Activity of some antileprosy compounds against Mycobacterium intracellulare in vitro. Am Rev Respir Dis. 1977 Apr;115(4):705–708. doi: 10.1164/arrd.1977.115.4.705. [DOI] [PubMed] [Google Scholar]
  10. Meissner G., Schröder K. H. Relationship between Mycobacterium simiae and Mycobacterium habana. Am Rev Respir Dis. 1975 Feb;111(2):196–200. doi: 10.1164/arrd.1975.111.2.196. [DOI] [PubMed] [Google Scholar]
  11. Moulding T. The relative drug susceptibility of opaque colonial forms of Mycobacterium intracellulare-avium: does it affect therapeutic results? Am Rev Respir Dis. 1978 Jun;117(6):1142–1143. doi: 10.1164/arrd.1978.117.6.1142. [DOI] [PubMed] [Google Scholar]
  12. Schaefer W. B., Davis C. L., Cohn M. L. Pathogenicity of transparent, opaque, and rough variants of Mycobacterium avium in chickens and mice. Am Rev Respir Dis. 1970 Oct;102(4):499–506. doi: 10.1164/arrd.1970.102.4.499. [DOI] [PubMed] [Google Scholar]
  13. Shronts J. S., Rynearson T. K., Wolinsky E. Rifampin alone and combined with other drugs in Mycobacterium kansasii and Mycobacterium intracellulare infections of mice. Am Rev Respir Dis. 1971 Nov;104(5):728–741. doi: 10.1164/arrd.1971.104.5.728. [DOI] [PubMed] [Google Scholar]
  14. Watson S. R., Collins F. M. Development of suppressor T cells in mice heavily infected with mycobacteria. Immunology. 1980 Mar;39(3):367–373. [PMC free article] [PubMed] [Google Scholar]
  15. Watson S. R., Collins F. M. Development of suppressor T-cells in Mycobacterium habana-infected mice. Infect Immun. 1979 Aug;25(2):497–506. doi: 10.1128/iai.25.2.497-506.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Watson S. R., Morrison N. E., Collins F. M. Delayed hypersensitivity responses in mice and guinea pigs to Mycobacterium leprae, Mycobacterium vaccae, and Mycobacterium nonchromogenicum cytoplasmic proteins. Infect Immun. 1979 Jul;25(1):229–236. doi: 10.1128/iai.25.1.229-236.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979 Jan;119(1):107–159. doi: 10.1164/arrd.1979.119.1.107. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES